# Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet

> **NCT00917644** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 76 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Atorvastatin
- **GENETIC:** Atorvastatin

## Key facts

- **NCT ID:** NCT00917644
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00917644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00917644, "Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00917644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*